#RAREis Global Advocate Grant initiative

#RAREis Global Advocate Grant initiative is sponsored by Horizon Therapeutics. This initiative awards grants to patient advocacy organizations globally that are focused on improving the lives of people with rare diseases.

Horizon Opens Applications for #RAREis Global Advocate Grant Program - Global Genes Horizon Opens Applications for #RAREis Global Advocate Grant Program Horizon Therapeutics opened applications for its 2023 #RAREis Global Advocate Grant, which are designed to support advocates addressing rare disease community needs. The #RAREis grant will provide 50 groups with a one-time $5,000 grant.

The 2023 effort represents a $100,000 increase over the previous year in which the company awarded 30 grants to advocacy organizations. The #RAREis Global Advocate Grant expands communication and awareness for the rare disease community by providing financial assistance to patient advocacy groups working to advance, educate, and address challenges faced by rare disease families.

The program aims to build equity for the rare disease community by empowering and fostering growth for small, often overlooked advocacy organizations around the world. The 30 organizations awarded the 2022 #RAREis Global Advocate Grant were from nine countries and represented 29 unique rare diseases.

Grant recipients used funding to establish new programs, develop educational resources, and expand their current offerings to support their disease communities. Applications are available at RAREiscommunity. com/Grant.

The deadline to apply is March 31, 2023. “Rare disease advocacy is often driven at the local level, propelled by families and people touched by a rare disorder, passionate about finding a cure and providing support for their loved ones,” said Matt Flesch, vice president, communications and patient advocacy for Horizon.

“The #RAREis Global Advocate Grant program provides essential one-time funding to increase the growth, reach, and impact of small, rare disease-focused non-profit organizations.

” Photo: Matt Flesch, vice president, communications and patient advocacy for Horizon podcast Rewiring the Rare Disease Diagnostic Odyssey Families seeking a diagnosis for a rare disease often face a protracted diagnostic odyssey that can include […] Deals Ipsen Expands Rare Disease Portfolio with $797 Million Acquisition of Memo Rare Daily Staff Paris-based Ipsen said it will acquire the Swiss biotech Memo Therapeutics in a deal […] Drug Development BioCryst to Scrap Internal Discovery Rare Daily Staff BioCryst Pharmaceuticals is shutting down its internal drug discovery operations and closing its Birmingham, […] Drug Development Gene Editing Therapy for Rare Immune Disorder Moves Closer to Clinic Rare Daily Staff A first-in-class gene therapy targeting CTLA-4 insufficiency, a rare and debilitating immune disorder, is […] Drug Development FDA Approves Viridian’s TED Therapy Rare Daily Staff The U.S. Food and Drug Administration has approved Viridian Therapeutics’ Lumvoa for thyroid eye […] Finance CIRM Issues $60 Million in Grants Including Funding for FOXG1 Gene Therapy Rare Daily Staff California Institute of Regenerative Medicine, the state’s stem cell agency, is issuing $60 million […] Deals Ionis Enters Global Licensing Deal with Recordati for Alexander disease ASO Rare Daily Staff Ionis Pharmaceuticals has struck a global licensing deal with Italy-based Recordati to bring its […] podcast Emerging from a Life in the Shadows Erythropoietic protoporphyria (EPP) is a rare, inherited metabolic disorder that triggers a toxic photochemical reaction in skin […] Finance UniQure Raises $225 Million to Back Accelerated Approval Bid for Huntington’s Gene Therapy Rare Daily Staff UniQure is capitalizing on an improved regulatory outlook for its experimental Huntington’s disease gene […] Facebook Twitter Instagram Youtube